Skip to content
2000
image of Hinokitiol as a Promising Anticancer Agent: Mechanisms of Action, Potential in Combination Therapy, and Overcoming Chemoresistance

Abstract

Cancer remains a major global health challenge, with conventional treatments such as chemotherapy and radiotherapy often lacking specificity and causing significant side effects. Hinokitiol, a natural tropolone derivative from the Cupressaceae family, has emerged as a promising anticancer agent due to its broad-spectrum activity. This review provides a comprehensive overview of hinokitiol’s anticancer properties, mechanisms of action, and safety profile. Hinokitiol has demonstrated potent effects across various cancer types, including breast, lung, prostate, colorectal, and melanoma. Its mechanisms include apoptosis induction, cell cycle arrest at the G1/S and G2/M checkpoints, inhibition of Epithelial-Mesenchymal Transition (EMT), suppression of metastasis, and iron chelation. Additionally, it may enhance chemosensitivity in cancer cells that are resistant to treatment. Importantly, this review identifies and discusses key research gaps limiting hinokitiol’s clinical translation. These include the absence of human clinical trials, limited pharmacokinetic and pharmacodynamic data, insufficient toxicity profiling, and context-dependent effects on cellular pathways such as ferroptosis and autophagy. We also highlight its unexplored potential in combination therapies aimed at overcoming multidrug resistance. By synthesizing current preclinical findings and outlining future research directions such as optimizing delivery systems, clarifying mechanisms in specific cancer contexts, and initiating clinical evaluation, this review contributes a critical perspective on the steps needed to develop hinokitiol as a viable anticancer therapeutic. Addressing these gaps could significantly enhance its therapeutic utility and integration into modern oncology.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128404533250915113223
2025-10-06
2026-02-25

  • From This Site

    /content/journals/cpd/10.2174/0113816128404533250915113223
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Jayakumar T. Liu C.H. Wu G.Y. Hinokitiol inhibits migration of A549 lung cancer cells via suppression of mmps and induction of antioxidant enzymes and apoptosis. Int. J. Mol. Sci. 2018 19 4 939 10.3390/ijms19040939 29565268
    [Google Scholar]
  2. El Hachlafi N. Lakhdar F. Khouchlaa A. Health benefits and pharmacological properties of hinokitiol. Processes 2021 9 9 1680 10.3390/pr9091680
    [Google Scholar]
  3. Karunakar K.K. Thanikachalam P.V. Dhanalakshmi S.M. Kesharwani P. Cheriyan B.V. Hinokitiol attenuates gentamicin-induced nephrotoxicity by reversing oxidative stress and inflammation. Pharmacol Res Mod Chin Med 2024 10 100410 10.1016/j.prmcm.2024.100410
    [Google Scholar]
  4. Chiang Y.F. Huang K.C. Chen H.Y. Hinokitiol inhibits breast cancer cells in vitro stemness-progression and self-renewal with apoptosis and autophagy modulation via the CD44/Nanog/SOX2/Oct4 pathway. Int. J. Mol. Sci. 2024 25 7 3904 10.3390/ijms25073904 38612715
    [Google Scholar]
  5. Isobe H. At the dawn of novel aromatics: “On the Synthesis of Hinokitiol” by Tetsuo Nozoe et al. Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci. 2023 99 10 427 437 10.2183/pjab.99.020 37648503
    [Google Scholar]
  6. Chen H.Y. Cheng W.P. Chiang Y.F. Hinokitiol exhibits antitumor properties through induction of ROS-mediated apoptosis and p53-driven cell-cycle arrest in endometrial cancer cell lines (Ishikawa, HEC-1A, KLE). Int. J. Mol. Sci. 2021 22 15 8268 10.3390/ijms22158268 34361036
    [Google Scholar]
  7. Shih Y.H. Chang K.W. Hsia S.M. In vitro antimicrobial and anticancer potential of hinokitiol against oral pathogens and oral cancer cell lines. Microbiol. Res. 2013 168 5 254 262 10.1016/j.micres.2012.12.007 23312825
    [Google Scholar]
  8. Huang C.H. Lu S.H. Chang C.C. Thomas P.A. Jayakumar T. Sheu J.R. Hinokitiol, a tropolone derivative, inhibits mouse melanoma (B16-F10) cell migration and in vivo tumor formation. Eur. J. Pharmacol. 2015 746 148 157 10.1016/j.ejphar.2014.11.011 25449038
    [Google Scholar]
  9. Zhao H. Zhang M. Zhang J. Hinokitiol-iron complex is a ferroptosis inducer to inhibit triple-negative breast tumor growth. Cell Biosci. 2023 13 1 87 10.1186/s13578‑023‑01044‑0 37179385
    [Google Scholar]
  10. van den Boogaard W.M.C. Komninos D.S.J. Vermeij W.P. Chemotherapy side-effects: Not all DNA damage is equal. Cancers 2022 14 3 627 10.3390/cancers14030627 35158895
    [Google Scholar]
  11. Islam M.R. Rauf A. Alash S. A comprehensive review of phytoconstituents in liver cancer prevention and treatment: Targeting insights into molecular signaling pathways. Med. Oncol. 2024 41 6 134 10.1007/s12032‑024‑02333‑5 38703282
    [Google Scholar]
  12. Hussain M.S. Altamimi A.S.A. Afzal M. Kaempferol: Paving the path for advanced treatments in aging-related diseases. Exp. Gerontol. 2024 188 112389 10.1016/j.exger.2024.112389 38432575
    [Google Scholar]
  13. Yi Q. Xu Z. Thakur A. Current understanding of plant-derived exosome-like nanoparticles in regulating the inflammatory response and immune system microenvironment. Pharmacol. Res. 2023 190 106733 10.1016/j.phrs.2023.106733 36931541
    [Google Scholar]
  14. Mattiuzzi C. Lippi G. Current cancer epidemiology. J. Epidemiol. Glob. Health 2019 9 4 217 222 10.2991/jegh.k.191008.001 31854162
    [Google Scholar]
  15. Yang P.S. Wang M.J. Jayakumar T. Antiproliferative activity of hinokitiol, a tropolone derivative, is mediated via the inductions of p-JNK and p-PLCγ1 signaling in PDGF-BB-stimulated vascular smooth muscle cells. Molecules 2015 20 5 8198 8212 10.3390/molecules20058198 25961161
    [Google Scholar]
  16. Yien Y.Y. Shi J. Chen C. FAM210B is an erythropoietin target and regulates erythroid heme synthesis by controlling mitochondrial iron import and ferrochelatase activity. J. Biol. Chem. 2018 293 51 19797 19811 10.1074/jbc.RA118.002742 30366982
    [Google Scholar]
  17. Yang S.C. Chen H.Y. Chuang W.L. Wang H.C. Hsieh C.P. Huang Y.F. Different cell responses to hinokitiol treatment result in senescence or apoptosis in human osteosarcoma cell lines. Int. J. Mol. Sci. 2022 23 3 1632 10.3390/ijms23031632 35163553
    [Google Scholar]
  18. Karunakar K.K. Cheriyan B.V. Velmurugan R. Gopalakrishnan M. Vs K. Mechanistic insights and therapeutic applications of hinokitiol in inflammation, antimicrobial therapy, and cancer. Pharmacol Res Mod Chin Med 2024 13 100527 10.1016/j.prmcm.2024.100527
    [Google Scholar]
  19. Chen X. Zhang X. Chen J. Hinokitiol copper complex inhibits proteasomal deubiquitination and induces paraptosis-like cell death in human cancer cells. Eur. J. Pharmacol. 2017 815 147 155 10.1016/j.ejphar.2017.09.003 28887042
    [Google Scholar]
  20. Seno S. Kimura M. Yashiro Y. β-Thujaplicin enhances TRAIL-induced apoptosis via the dual effects of XIAP inhibition and degradation in NCI-H460 human lung cancer cells. Medicines 2021 8 6 26 10.3390/medicines8060026 34199423
    [Google Scholar]
  21. Huang C.H. Jayakumar T. Chang C.C. Hinokitiol exerts anticancer activity through downregulation of MMPs 9/2 and enhancement of catalase and SOD enzymes: In vivo augmentation of lung histoarchitecture. Molecules 2015 20 10 17720 17734 10.3390/molecules201017720 26404213
    [Google Scholar]
  22. Makhov P. Golovine K. Uzzo R.G. Zinc chelation induces rapid depletion of the X-linked inhibitor of apoptosis and sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Cell Death Differ. 2008 15 11 1745 1751 10.1038/cdd.2008.106 18617897
    [Google Scholar]
  23. Morita Y. Matsumura E. Tsujibo H. Biological activity of 4-acetyltropolone, the minor component of Thujopsis dolabrata SIeb. et Zucc. hondai Mak. Biol. Pharm. Bull. 2002 25 8 981 985 10.1248/bpb.25.981 12186430
    [Google Scholar]
  24. Yasumoto E. Nakano K. Nakayachi T. Cytotoxic activity of deferiprone, maltol and related hydroxyketones against human tumor cell lines. Anticancer Res. 2004 24 2B 755 762 15161023
    [Google Scholar]
  25. Sanchez-Sanchez A. Akbari S. Moreno A.J. Design and preparation of single-chain nanocarriers mimicking disordered proteins for combined delivery of dermal bioactive cargos. Macromol. Rapid Commun. 2013 34 21 1681 1686 10.1002/marc.201300562 24115236
    [Google Scholar]
  26. Chen S.M. Wang B.Y. Lee C.H. Hinokitiol up-regulates miR-494-3p to suppress BMI1 expression and inhibits self-renewal of breast cancer stem/progenitor cells. Oncotarget 2017 8 44 76057 76068 10.18632/oncotarget.18648 29100291
    [Google Scholar]
  27. Xi J. Zhang Z. Wang Z. Hinokitiol functions as a ferroptosis inhibitor to confer neuroprotection. Free Radic. Biol. Med. 2022 190 202 215 10.1016/j.freeradbiomed.2022.08.011 35985562
    [Google Scholar]
  28. Ni Y.J. Huang Z.N. Li H.Y. Hinokitiol impedes tumor drug resistance by suppressing protein kinase B/mammalian targets of rapamycin axis. J. Cancer 2022 13 6 1725 1733 10.7150/jca.69449 35399709
    [Google Scholar]
  29. Wang W.K. Lin S.T. Chang W.W. Hinokitiol induces autophagy in murine breast and colorectal cancer cells. Environ. Toxicol. 2016 31 1 77 84 10.1002/tox.22023 25044443
    [Google Scholar]
  30. Wang C.C. Chen B.K. Chen P.H. Chen L.C. Hinokitiol induces cell death and inhibits epidermal growth factor-induced cell migration and signaling pathways in human cervical adenocarcinoma. Taiwan. J. Obstet. Gynecol. 2020 59 5 698 705 10.1016/j.tjog.2020.07.013 32917321
    [Google Scholar]
  31. Li L.H. Wu P. Lee J.Y. Hinokitiol induces DNA damage and autophagy followed by cell cycle arrest and senescence in gefitinib-resistant lung adenocarcinoma cells. PLoS One 2014 9 8 104203 10.1371/journal.pone.0104203 25105411
    [Google Scholar]
  32. Seo J.S. Choi Y.H. Moon J.W. Kim H.S. Park S.H. Hinokitiol induces DNA demethylation via DNMT1 and UHRF1 inhibition in colon cancer cells. BMC Cell Biol. 2017 18 1 14 10.1186/s12860‑017‑0130‑3 28241740
    [Google Scholar]
  33. Lee Y.S. Choi K.M. Kim W. Hinokitiol inhibits cell growth through induction of S-phase arrest and apoptosis in human colon cancer cells and suppresses tumor growth in a mouse xenograft experiment. J. Nat. Prod. 2013 76 12 2195 2202 10.1021/np4005135 24308647
    [Google Scholar]
  34. Tsao YT Huang YF Kuo CY Hinokitiol inhibits melanogenesis via AKT/mTOR signaling in B16F10 mouse melanoma cells. int j mol sci 2016 17 2 248 10.3390/ijms17020248 26901194
    [Google Scholar]
  35. Yang H.W. Lu M.Y. Chiu Y.W. Hinokitiol ablates myofibroblast activation in precancerous oral submucous fibrosis by targeting Snail. Environ. Toxicol. 2018 33 4 454 462 10.1002/tox.22531 29328529
    [Google Scholar]
  36. Tanaka T. Muto N. Ido Y. Itoh N. Tanaka K. Induction of embryonal carcinoma cell differentiation by deferoxamine, a potent therapeutic iron chelator. Biochim. Biophys. Acta Mol. Cell Res. 1997 1357 1 91 97 10.1016/S0167‑4889(97)00016‑5 9202179
    [Google Scholar]
  37. Chen C. Garcia-Santos D. Ishikawa Y. Snx3 regulates recycling of the transferrin receptor and iron assimilation. Cell Metab. 2013 17 3 343 352 10.1016/j.cmet.2013.01.013 23416069
    [Google Scholar]
  38. Grillo A.S. SantaMaria A.M. Kafina M.D. Restored iron transport by a small molecule promotes absorption and hemoglobinization in animals. Science 2017 356 6338 608 616 10.1126/science.aah3862 28495746
    [Google Scholar]
  39. Dixon S.J. Lemberg K.M. Lamprecht M.R. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 2012 149 5 1060 1072 10.1016/j.cell.2012.03.042 22632970
    [Google Scholar]
  40. Stockwell B.R. Friedmann Angeli J.P. Bayir H. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell 2017 171 2 273 285 10.1016/j.cell.2017.09.021 28985560
    [Google Scholar]
  41. Andrews N.C. Disorders of iron metabolism. N. Engl. J. Med. 1999 341 26 1986 1995 10.1056/NEJM199912233412607 10607817
    [Google Scholar]
  42. Perri F. Pacelli R. Della Vittoria Scarpati G. Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications. Head Neck 2015 37 5 763 770 10.1002/hed.23837 24995469
    [Google Scholar]
  43. Haas M. Lenz T. Kadletz-Wanke L. Heiduschka G. Jank B.J. The radiosensitizing effect of β-Thujaplicin, a tropolone derivative inducing S-phase cell cycle arrest, in head and neck squamous cell carcinoma-derived cell lines. Invest. New Drugs 2022 40 4 700 708 10.1007/s10637‑022‑01229‑3 35412173
    [Google Scholar]
  44. Nanayakkara A.K. Follit C.A. Chen G. Williams N.S. Vogel P.D. Wise J.G. Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells. Sci. Rep. 2018 8 1 967 10.1038/s41598‑018‑19325‑x 29343829
    [Google Scholar]
/content/journals/cpd/10.2174/0113816128404533250915113223
Loading
Hinokitiol as a Promising Anticancer Agent: Mechanisms of Action, Potential in Combination Therapy, and Overcoming Chemoresistance
Bentham Science Publishers ; https://doi.org/10.2174/0113816128404533250915113223
/content/journals/cpd/10.2174/0113816128404533250915113223
/content/journals/cpd/10.2174/0113816128404533250915113223
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: synergistic therapy ; ferroptosis ; Cell cycle arrest ; chemoresistance ; nanoparticle delivery ; tumor suppressor proteins

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test